Biocartis Granted $1.5M to Develop Liquid Biopsy Version of KRAS, BRAF Tests | GenomeWeb

NEW YORK (GenomeWeb) – Belgian MDx Firm Biocartis announced today that it has received a €1.4 million ($1.5 million) grant from the Flemish Agency for Innovation by Science and Technology (IWT) to support the development of liquid biopsy versions of its solid tumor BRAF and KRAS diagnostics for melanoma and colorectal cancer.

The funds, made as part of an IWT-subsidized collaboration project called Early Diagnosis by Easy Sampling, will also support more general research on improved liquid biopsy methodologies, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.